financetom
Business
financetom
/
Business
/
2seventy Bio stops enrolling patients in blood cancer therapy study
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
2seventy Bio stops enrolling patients in blood cancer therapy study
Sep 26, 2024 10:46 AM

Sept 25 (Reuters) - 2seventy bio on Wednesday

said it would discontinue enrolling new patients in the

late-stage study for its cell therapy to treat newly diagnosed

myeloma, which is a type of blood cancer.

(Reporting by Kashish Tandon in Bengaluru; Editing by Abinaya

Vijayaraghavan)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved